Wesson DE, et al. - Via a multicentre, parallel, randomized, double-blind, placebo-controlled study performed at 37 sites (hospitals and specialty clinics) in Bulgaria, Croatia, Georgia, Hungary, Serbia, Slovenia, Ukraine, and the USA, researchers examined the efficacy and safety of veverimer treatment for metabolic acidosis in patients with chronic kidney disease. They randomly assigned 124 participants to veverimer and 93 to placebo. Outcomes support that metabolic acidosis could be safely and effectively corrected using veverimer treatment. Treatment-related adverse events mostly comprised gastrointestinal (diarrhoea, flatulence, nausea, and constipation) events that occurred in 16 (13%) patients with veverimer and five (5%) patients with placebo.